Apellis Pharmaceuticals :
APLS
APLS
Stock Data
$41.03
$0.00 (0.00%)
Asset Type
N/A
Exchange
N/A
Currency
N/A
Country
N/A
Sector
N/A
Industry
N/A
Apellis Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to developing innovative treatments for autoimmune and inflammatory diseases by targeting the complement system. Its flagship product, EMPAVELI, is designed for various conditions including paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. Apellis is also advancing SYFOVRE for age-related macular degeneration and has other promising therapies in early-stage trials. Founded in 2009 and headquartered in Waltham, Massachusetts, the company collaborates with industry leaders to enhance its drug development pipeline.
All Apellis Pharmaceuticals Articles
13 Articles